Michael Kos, MD
Radiation Oncology · Spokane Valley, WANPI 1366599631
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,000 of the $6,411 with a category attached, or 62.4%. 28 manufacturers reported payments, led by Photocure Inc at 47.4% of the total. Reporting peaked in 2022 at $3,366 and has fallen 95.5% since, to $152 in 2025. Among radiation oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $101.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Photocure Inc$3K
- Bioprotect Medical, Inc.$2K
- AbbVie$213
- AstraZeneca$211
- Bayer$160
- Bristol Myers Squibb$137
- plus $869 from 22 others
What the payments were for
- Speaking & faculty fees$4,00062%
- Travel & lodging$78812%
- Food & beverage$1,62325%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Photocure Inc | 4 | $3,038 |
| Bioprotect Medical, Inc. | 2 | $1,783 |
| AbbVie | 11 | $213 |
| AstraZeneca(2 entities) | 5 | $211 |
| Bayer | 7 | $160 |
| Bristol Myers Squibb | 1 | $137 |
| Telix Pharmaceuticals | 1 | $125 |
| Elekta, Inc. | 2 | $115 |
| Boston Scientific | 6 | $115 |
| Johnson & Johnson | 4 | $83 |
| Dendreon Pharmaceuticals LLC | 3 | $51 |
| Pharmacosmos Therapeutics Inc. | 1 | $34 |
| Octapharma USA, Inc. | 1 | $32 |
| Iovance Biotherapeutics, Inc. | 1 | $28 |
| Agios Pharmaceuticals, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Merck | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Sobi, Inc | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $23 |
| Exelixis Inc. | 1 | $22 |
| Amgen | 1 | $19 |
| Seagen Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cysview$3,038
- BIOPROTECT BALLOON IMPLANT SYSTEM$1,750
- ILLUCCIX$250
- Revlimid$137
- IMFINZI$125
How this compares
$6,411 in reported general payments places this provider in the 90th percentile of 168 radiation oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 18 | $102 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Spokane Valley
- Christopher LeeSpokane Valley$138K
- Robin SmithSpokane Valley$2K
- Wayne LamoreauxSpokane Valley$1K
- Vivek MehtaSeattle$120K
- Christopher LoiselleSeattle$63K
- Ramesh RenganSeattle$57K
- Jing ZengSeattle$37K
- Omar MianSeattle$22K
- Susan GuoTacoma$18K
- Richard HsiSeattle$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.